An exploratory analysis of patent fencing in pharmaceuticals: The case of PDE5 inhibitors

Research Policy

Volumn 42, Issue 2, 2013, Pages 542-551

  Sternitzke, Christian ^a,b  

^a CFH Beteiligungsgesellschaft MbH   (Germany)

^b ILMENAU UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Blocking; Complementary patents; Drug lifecycle management; Patent fencing; Substitutive patents

Indexed keywords

LIFE CYCLE;

BLOCKING; COMPLEMENTARY PATENTS; LIFE-CYCLE MANAGEMENT; PATENT FENCING; SUBSTITUTIVE PATENTS;

PATENTS AND INVENTIONS;

EID: 84874772384     PISSN: 00487333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.respol.2012.11.003     Document Type: Article

References (53)

1. I. Agranat, and S.R. Wainschtein The strategy of enantiomer patents of drugs Drug Discovery Today 15 2010 163 170
2. A. Arundel, and I. Kabla What percentage of innovations are patented? Empirical estimates for European firms Research Policy 27 1998 127 141
3. Arundel, A.; van de Paal, G.; Soete, L.; 1995. Innovation strategies of Europe's largest industrial firms: results of the survey for information sources, public research, protection of innovations and government programmes. PACE Report. MERIT, Maastricht.
4. J.B. Barney Gaining and Sustaining Competitive Advantage 1997 Addison-Wesley Reading, MA
5. E.R. Berndt, R.S. Pindyck, and P. Azoulay Consumption externalities and diffusion in pharmaceutical markets: antiulcer drugs The Journal of Industrial Economics 51 2003 243 270
6. V.N. Bhat Patent term extension strategies in the pharmaceutical industry Pharmaceuticals Policy and Law 6 2005 109 122
7. K. Blind, J. Edler, R. Frietsch, and U. Schmoch Motives to patent: empirical evidence from Germany Research Policy 35 2006 655 672
8. Business Week. The Most Counterfeited Products-Pfizer Viagra (downloaded on 16 October 2012 from http://www.businessweek.com/images/ss/08/10/1002- counterfeit/14.htm).
9. M. Ceccagnoli Appropriability, preemption, and firm performance Strategic Management Journal 30 2009 81 98
10. C.R. Chong, and D.J. Sullivan Jr. New uses for old drugs Nature 448 2007 645 646
11. A.F. Christie, and C. Dent Non-overlapping rights: a patent misconception European Intellectual Property Review 32 2010 58 66
12. G. Clarkson, and D. DeKorte The problem of patent thickets in convergent technologies Annals of the New York Academy of Sciences 1093 2006 180 200
13. I. Cockburn, and R. Henderson Racing to invest? The dynamics of competition in ethical drug discovery Journal of Economics Management Strategy 3 1994 481 519
14. W.M. Cohen, A. Goto, A. Nagata, R.R. Nelson, and J.P. Walsh R&D spillovers, patents and the incentives to innovate in Japan and the United States Research Policy 31 2002 1349 1367
15. Cohen, W.M.; Nelson, R.R.; Walsh, J.; 2000. Protecting Their Intellectual Assets: Appropriability Conditions and Why US Manufacturing Firms Patent (or Not). NBER Working Paper No. 7552.
16. J.A. DiMasi, and C. Paquette The economics of follow-on drug research and development Pharmacoeconomics 22 2004 1 14
17. P. Dorsey, C. Keel, M. Klavens, and W.J.G. Hellstrom Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction Expert Opinion on Pharmacotherapy 11 2010 1109 1122
18. K.M. Eisenhardt Building theories from case study research Academy of Management Review 14 1989 532 550
19. A.B. Engelberg Special patent provisions for pharmaceuticals: have they outlived their usefullness-a political legislative and legal history of US law and obersvations for the future IDEA-The Journal of Law and Technology 39 1998 389 428
20. H. Ernst Patent applications and subsequent changes of performance: evidence from time-series cross-section analyses on the firm level Research Policy 30 2001 143 158
21. European Generic Medicines Association. Pharmaceutical Patents (downloaded on 21 January 2012 from http://www.egagenerics.com/gen-phrmapatents. htm).
22. Federal Trade Commission, 2002. Generic drug entry prior to patent expiration: an FTC study (downloaded on 12 May 2012 from http://www.ftc.gov/os/ 2002/07/genericdrugstudy.pdf).
23. K. Girotra, C. Terwiesch, and K.T. Ulrich Valuing R&D projects in a portfolio: evidence from the pharmaceutical industry Management Science 53 2007 1452 1466
24. D.I. Gorlin Staving off death: a case study of the pharmaceutical industry's strategies to protect blockbuster franchises Food and Drug Law Journal 63 2008 823 864
25. O. Granstrand The Economics and Management of Intellectual Property 1999 Edgar Elgar Cheltenham
26. P.C. Grindley, and D.J. Teece Managing intellectual capital: licensing and cross-licensing in semiconductors and electronics California Management Review 39 1997 8 41
27. M.A. Heller, and R.S. Eisenberg Can patents deter innovation? The anticommons in biomedical research Science 280 1998 698
28. L. Howard Use of patents in drug lifecycle management Journal of Generic Medicines 4 2007 230 236
29. M. Hutchins Extending the monopoly: how "secondary" patents can be used to delay or prevent generic competition upon expiry of the basic product patent Journal of Generic Medicine 1 2003 57 71
30. L. Katzenstein, and E.B. Grossman Viagra (sildenafil citrate): The Remarkable Story of The Discovery and Launch 2001 Medical Information Press New York
31. A.S. Kesselheim Intellectual property policy in the pharmaceutical sciences: the effect of inappropriate patents and market exclusivity extensions on the health care system AAPS Journal 9 2007 E306 E311
32. R.C. Levin, A.K. Klevorick, R.R. Nelson, and S.G. Winter Appropriating the returns from industrial research and development Brookings Papers on Economic Activity 1987 Brookings Institution Washington, DC
33. E. Mansfield Patents and innovation: an empirical study Management Science 32 1986 173 181
34. E. Mansfield, M. Schwartz, and S. Wagner Imitation costs and patents: an empirical study Economic Journal 91 1981 907 918
35. G.D. Markman, M.I. Espina, and P.H. Phan Patents as surrogates for inimitable and non-substitutable resources Journal of Management 30 2004 529 544
36. M.P. Mathieu Parexel's Pharmaceutical R&D Statistical Sourcebook 2006/2007 2005 Parexel International Corp.
37. C.S. Paine Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering Seton Hall Law Review 33 2002 479 510
38. A.M. Pettigrew Longitudinal field research on change: theory and practice Organization Science 1 1990 267 292
39. PhRMA, 2007. Drug discovery and development (downloaded on 22 February 2010 from http://www.phrma.org/files/attachments/RD%20Brochure%20022307.pdf).
40. A. Raasch Der Patentauslauf von Pharmazeutika als Herausforderung beim Management des Produktlebenszyklus: Strategische Optionen und ihre erfolgreiche Umsetzung in Marketing und Vertrieb 2006 DUV Wiesbaden
41. G. Rahn Patentstrategien japanischer Unternehmen Gewerblicher Rechtsschutz und Urheberrecht (International) 1994 377 382
42. M. Reitzig The private value of thickets and fences: towards an updated picture of the use of patents across industries Economics of Innovation and New Technology 13 2004 457 476
43. M. Reitzig, and P. Puranam Value appropriation as an organizational capability: the case of IP protection through patents Strategic Management Journal 30 2009 765 789
44. K.G. Rivette, and D. Kline Discovering new value in intellectual property Harvard Business Review 78 2000 54 67
45. P. Sandner, and K. Ziegelbauer Product-related research: how research can contribute to successful life-cycle management Drug Discovery Today 13 2008 457 463
46. C. Shapiro Navigating the patent thicket: cross licenses, patent pools, and standard setting Innovation Policy and the Economy 1 2001 119 150
47. D. Somaya, I.O. Williamson, and X. Zhang Combining patent law expertise with R&D for patenting performance Organization Science 18 2007 922 937
48. C. Sternitzke The international preliminary examination of patent applications according to the Patent Cooperation Treaty-a proxy for patent value? Scientometrics 78 2009 189 202
49. C. Sternitzke Knowledge sources, patent protection, and commercialization of pharmaceutical innovations Research Policy 39 2010 810 821
50. P. Trott Innovation Management and New Product Development 4th ed. 2008 Pearson Harlow
51. von Graevenitz, G.; Wagner, S.; Harhoff, D.; 2008. Incidence and growth of patent thickets-the impact of technological opportunities and complexity. CEPR discussion paper number DP6900 (available via SSRN).
52. B. Whitehead, S. Jackson, and R. Kempner Managing generic competition and patent strategies in the pharmaceutical industry Journal of Intellectual Property Law & Practice 3 2008 226
53. R.H. Ziedonis Don't fence me in: fragmented markets for technology and the patent acquisition strategies of firms Management Science 50 2004 804 820